title: Mesothelial cell and anti-nuclear autoantibodies associated with pleural abnormalities in an asbestos exposed population of Libby MT.
abstract: Despite data linking amphibole asbestos exposure with production of autoantibodies, the role of autoantibodies in subsequent disease is unknown. Residents of Libby, Montana have experienced significant exposure to amphibole asbestos due to the mining of asbestos-contaminated vermiculite near the community over several decades. This population predominantly exhibits pleural disease, and an autoimmune-like disorder that has yet to be well defined. This study sought to determine whether autoantibodies from asbestos-exposed subjects were associated with pleural lesions. Serum samples of subjects from Libby were evaluated for anti-nuclear antibodies (ANA) and mesothelial cell autoantibodies (MCAA) using cell based ELISA. The presence of radiographic abnormalities detected during the time frame of serum collection was determined from screening records. In accord with previous studies, 61.3% (76/124) of the Libby samples were ANA positive, a frequency much higher than expected for a healthy population. The odds of having pleural or interstitial abnormalities in Libby was nearly 3.55 times greater for individuals that tested positive for ANA compared with individuals negative for ANA (p=0.004). MCAA were also detected at a strikingly high frequency (18.5%; 23/124) in samples from Libby. Individuals with MCAA had 4.9 times the risk of having pleural abnormalities compared to MCAA-negative subjects (p=0.044). In conclusion, ANA and MCAA were elevated in a study population that was known to have chronic exposure to asbestos, and these autoantibodies were associated with pleural abnormalities, the predominant finding in the asbestos-exposed population of Libby. Additional research is needed to determine the role these autoantibodies may play in pulmonary disease.
authors.affiliation: Department of Biological Sciences, Idaho State University, 921 South 8th Ave., Pocatello, ID 83209, USA.
authors.forename: Lucas S
authors.initials: LS
authors.lastname: Marchand
authors.forename: Sophie
authors.initials: S
authors.lastname: St-Hilaire
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Putnam
authors.forename: Kinta M
authors.initials: KM
authors.lastname: Serve
authors.forename: Jean C
authors.initials: JC
authors.lastname: Pfau
mesh_terms: D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000097:blood / Q000276:immunology*; D001195:Asbestosis / Q000276:immunology*; D004781:Environmental Exposure / Q000009:adverse effects*; D004797:Enzyme-Linked Immunosorbent Assay; D004848:Epithelium / Q000276:immunology*; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009009:Montana / Q000453:epidemiology; D010995:Pleural Diseases / Q000139:chemically induced* / Q000276:immunology; D011859:Radiography; D055815:Young Adult
chemical_list: D000974:Antibodies, Antinuclear
references.citation: Environ Health Perspect. 2003 Nov;111(14):1753-9
references.pmid: 14594627
references.citation: Toxicology. 2008 Apr 18;246(2-3):172-9
references.pmid: 18295955
references.citation: Arthritis Rheum. 1997 Sep;40(9):1601-11
references.pmid: 9324014
references.citation: Indian J Med Res. 1993 Dec;98:274-7
references.pmid: 8132229
references.citation: Am J Ind Med. 2004 Sep;46(3):219-25
references.pmid: 15307120
references.citation: Occup Environ Med. 2004 Apr;61(4):363-6
references.pmid: 15031396
references.citation: Toxicology. 2002 Dec 27;181-182:65-70
references.pmid: 12505286
references.citation: Environ Health Perspect. 2006 Aug;114(8):1243-7
references.pmid: 16882533
references.citation: Nat Rev Rheumatol. 2010 May;6(5):280-9
references.pmid: 20431553
references.citation: Arthritis Rheum. 2002 Jun;46(6):1602-13
references.pmid: 12115192
references.citation: Int Arch Arbeitsmed. 1974 Jan 31;32(4):313-25
references.pmid: 4821458
references.citation: Ann N Y Acad Sci. 1965 Dec 31;132(1):112-20
references.pmid: 5219543
references.citation: Br Med J. 1970 Aug 29;3(5721):492-5
references.pmid: 4918296
references.citation: Int J Hyg Environ Health. 2005;208(1-2):55-65
references.pmid: 15881979
references.citation: Inhal Toxicol. 2006 Nov;18(12):949-62
references.pmid: 16920668
references.citation: Environ Health Perspect. 2008 Jun;116(6):695-702
references.pmid: 18560522
references.citation: Environ Health Perspect. 2005 Jan;113(1):25-30
references.pmid: 15626643
references.citation: Inhal Toxicol. 2005 Aug;17(9):427-49
references.pmid: 16020039
references.citation: J Toxicol Environ Health B Crit Rev. 2011;14(1-4):122-52
references.pmid: 21534087
references.citation: Arthritis Rheum. 2006 Mar;54(3):963-73
references.pmid: 16508979
references.citation: Curr Opin Rheumatol. 2006 Nov;18(6):579-81
references.pmid: 17053501
references.citation: Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v14-5
references.pmid: 18784128
references.citation: Sangyo Igaku. 1993 Sep;35(5):406-12
references.pmid: 8230802
references.citation: Inhal Toxicol. 2010 Oct;22(12):984-98
references.pmid: 20718637
references.citation: Sangyo Eiseigaku Zasshi. 1996 May;38(3):138-41
references.pmid: 8689500
references.citation: Science. 1990 Jan 19;247(4940):294-301
references.pmid: 2153315
references.citation: Am J Ind Med. 1982;3(3):259-311
references.pmid: 7171087
references.citation: J Immunotoxicol. 2005 Jul 1;1(3):177-87
references.pmid: 18958651
references.citation: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Sep-Oct;1(5):511-29
references.pmid: 20049814